Effective and Efficient Platforms
Producing Oncolytic VSV In Situ
Producing Oncolytic VSV In Situ
Producing Oncolytic VSV In Situ
Large-scale manufacturing of VSV is time-consuming and labor-intensive. Our superior VSV rescue efficiency will enable us to recover and produce VSV from tumor tissue directly.
Novel RNA Delivery System
Producing Oncolytic VSV In Situ
Producing Oncolytic VSV In Situ
The new system has better delivery efficiency than the LNP platform and is highly immunogenic, which is great for mRNA-based vaccines.
Producing RNA In Vivo
Producing Oncolytic VSV In Situ
Producing RNA In Vivo
Current IVT methods use high magnesium concentrations to boost productivity, but this comes at the expense of fidelity and results in a high level of byproducts. Producing RNA in vivo not only ensures product quality but more cost-effective.